BI-7273 is a potent and selective BRD9 inhibitor with IC50s of 19 nM and 117 nM for BRD9 and BRD7, respectively. BI-7273 blocks EOL-1 cell proliferation with EC50 of 1400 nM. In vitro, BI-7273 (1 μM) is active in U2OS cell lines.
|Animal models||Female BomTac:NMRI-Foxn1nu mice|
|Dosages||20 and 180 mg/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 40 mg/mL|
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ, et al. J Med Chem. 2016 May 26;59(10):4462-75. PMID: 26914985.
|Related Epigenetic Reader Domain Products|
|AZD-5153 HNT salt
AZD-5153 HNT salt is a potent, selective and orally available BET/BRD4 bromodomain inhibitor, disrupts BRD4 with an IC50 of 1.7 nM.
ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 shows affinity to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively.
666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM.
|JQ-1 carboxylic acid
(+)-JQ1 carboxylic acid is the carboxylic acid form of (+)-JQ1 for derivative synthesis.
AZD9496 is an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1 mutant breast tumours in preclinical models.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.